Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

Hoth Therapeutics, Inc. (NASDAQ: HOTH)

Next Super Stock investor conference presentation 9/26/2019

Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, and acne.

Dermatology is a hot sector, and Pfizer (NYSE: PFE) recently paid $4.9 billion for HOTH peer company, Anacor whose lead product, Eucrisa, is a topical treatment for mild to moderate eczema.

With a shortened path towards regulatory approval, unique technology, and multiple near-term catalysts for value creation, HOTH represents a compelling opportunity. 

Watch this presentation as CEO Robb Knie explain’s HOTH’s unique value proposition for investors.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.